Tag Archives: Bluebird Bio Inc.

ASCO, aka The Oncology Super Bowl for Biotechs, sends stocks in every direction

Steve’s Take: As another jam-packed annual meeting of the American Society of Clinical Oncology in Chicago wrapped up on Tuesday (June 6, 2017), with some 38,000 oncologists gathering together at… Read more »

Global outlook for biotech IPOs looks bright; will “precision” and “convergence” be the new mantras?

Many investors typically start the New Year searching for prescient predictions. Armed with a raft of “foolproof” data they then take an oath to stick with new, rock-solid resolutions, usually,… Read more »

Arrowhead Pharma obliterated after ditching Hep B candidate; oh, that’s right, biotechs are risky

Shares of Arrowhead Pharmaceuticals Inc. (Pasadena CA) cratered 69% to $1.44 last week (November 28 to December 2, 2016) after the company said it would stop developing all drugs being… Read more »